Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

mesenchymal stromal cells-derived exosomes with KRAS G12D siRNA

Exosomes derived from mesenchymal stromal cells (MSCs) that have been engineered to carry short interfering RNA (siRNA) specific to the KRAS G12D mutation subtype. Upon administration, the KRAS G12D siRNA-loaded exosomes deliver siRNA to tumor cells expressing the mutant form of KRAS, potentially silencing its activity. The KRAS G12D mutation is thought to drive tumorigenesis and progression in some cancers.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	KrasG12D siRNA-loaded mesenchymal stromal cells-derived exosomes MSC-derived exosomes with KrasG12D siRNA

mesenchymal stromal cells-derived exosomes with KRAS G12D siRNA

Search NCI's Drug Dictionary